Open AccessA pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206
Author(s) -
Marisa Tungsiripat,
Douglas Kitch,
Marshall J. Glesby,
Samir K. Gupta,
John W. Mellors,
Laura Moran,
Lynne Jones,
Beverly Alston-Smith,
James F. Rooney,
Judith A. Aberg
Publication year - 2010
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e32833ad8b4
Subject(s) - dyslipidemia , placebo , regimen , antiretroviral therapy , medicine , crossover study , human immunodeficiency virus (hiv) , efavirenz , antiretroviral drug , pharmacology , ritonavir , lipoprotein , cholesterol , viral load , virology , alternative medicine , pathology , obesity
Several studies have reported improvement in lipids after antiretroviral therapy switches to tenofovir disoproxil fumarate (TDF)-containing regimens. We assessed lipid-lowering effects of TDF by adding it to a stable antiretroviral therapy regimen in this double-blind, placebo-controlled crossover study. We demonstrated that nonhigh-density lipoprotein cholesterol, low-density lipoprotein cholestrol, and total cholestrol improved significantly over TDF vs. placebo treatment in HIV-infected individuals with dyslipidemia. Adding TDF to stable, virologically suppressive antiretroviral therapy regimens improved lipid parameters, supporting a lipid-lowering effect of TDF.